Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance.

Body weight homeostasis is regulated by central and peripheral mechanisms, in which cytokines appear to have an important role.The circulating levels of the cytokines interleukin 1 (IL-1) and interleukin 18 (IL-18), and of inflammatory mediators such as prostaglandin E2 (PGE2), amongst others, are elevated in obese individuals. The low-grade inflammation associated with obesity may contribute to the development of insulin resistance, impaired glucose tolerance and type 2 diabetes. This review highlights results of studies in mice which indicate important roles for these proinflammatory cytokines during the development of obesity and insulin resistance, and in the treatment of type 2 diabetes.

[1]  S. Brownell,et al.  Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. , 2008, Cytokine.

[2]  H. Beydoun,et al.  Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta‐analysis , 2008, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[3]  S. Malozowski,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[4]  E. Zorrilla,et al.  Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency , 2007, Proceedings of the National Academy of Sciences.

[5]  S. Narumiya,et al.  Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.

[6]  S. Brownell,et al.  Night eating and obesity in the EP3R-deficient mouse , 2007, Proceedings of the National Academy of Sciences.

[7]  B. Saltin,et al.  Adipose Tissue Interleukin‐18 mRNA and Plasma Interleukin‐18: Effect of Obesity and Exercise , 2007, Obesity.

[8]  U. Andersson,et al.  Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. , 2007, Arthritis and rheumatism.

[9]  E. Montanya,et al.  Adenoviral overproduction of interleukin-1 receptor antagonist increases beta cell replication and mass in syngeneically transplanted islets, and improves metabolic outcome , 2007, Diabetologia.

[10]  P. Heinrich,et al.  Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP , 2007, Journal of Biological Chemistry.

[11]  B. Beutler,et al.  TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. , 2006, Current pharmaceutical design.

[12]  J. Dayer,et al.  Adipose Tissue Has Anti‐Inflammatory Properties , 2006, Annals of the New York Academy of Sciences.

[13]  Shizuo Akira,et al.  Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance , 2006, Nature Medicine.

[14]  L. Haupt,et al.  TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue — influence of BMI and adipose distribution , 2006, Diabetes & vascular disease research.

[15]  C. Ohlsson,et al.  Mature-Onset Obesity in Interleukin-1 Receptor I Knockout Mice , 2006, Diabetes.

[16]  K. Flegal,et al.  Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.

[17]  M. Lazarus.  The differential role of prostaglandin E2 receptors EP3 and EP4 in regulation of fever. , 2006, Molecular nutrition & food research.

[18]  Y. Iwakura,et al.  Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. , 2006, Diabetes.

[19]  C. Dinarello.  Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. , 2006, The American journal of clinical nutrition.

[20]  A. Charollais,et al.  Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents , 2006, Diabetologia.

[21]  M. Cork,et al.  Interleukin-1: a key inflammatory mediator in psoriasis? , 2006, Cytokine.

[22]  J. Dayer,et al.  Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. , 2005, Diabetes.

[23]  J. Meer,et al.  Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. , 2005, The Netherlands journal of medicine.

[24]  J. Beilby,et al.  Elevated Interleukin-18 Levels Are Associated With the Metabolic Syndrome Independent of Obesity and Insulin Resistance , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[25]  H. Kolb,et al.  The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. , 2005, European journal of endocrinology.

[26]  P. Reddy.  Interleukin-18: recent advances , 2004, Current opinion in hematology.

[27]  D. Weissman,et al.  Inhibition of Toll-like Receptor and Cytokine Signaling—A Unifying Theme in Ischemic Tolerance , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  R. Ji,et al.  Cell Signaling and the Genesis of Neuropathic Pain , 2004, Science's STKE.

[29]  S. Miller,et al.  Microglia Initiate Central Nervous System Innate and Adaptive Immune Responses through Multiple TLRs1 , 2004, The Journal of Immunology.

[30]  T. Oka.  Prostaglandin E2 as a mediator of fever: the role of prostaglandin E (EP) receptors. , 2004, Frontiers in bioscience : a journal and virtual library.

[31]  M. Reitman,et al.  Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. , 2004, Endocrinology.

[32]  D. Richel,et al.  Prostanoids and prostanoid receptors in signal transduction. , 2004, The international journal of biochemistry & cell biology.

[33]  V. Giusti,et al.  Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. , 2004, The Journal of clinical endocrinology and metabolism.

[34]  M. Carty,et al.  Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. , 2004, Diabetes.

[35]  C. Stansberg,et al.  The interleukin 1 receptor family. , 2004, Developmental and comparative immunology.

[36]  A. A. Romanovsky,et al.  Prostaglandin E2 as a mediator of fever: synthesis and catabolism. , 2004, Frontiers in bioscience : a journal and virtual library.

[37]  B. Beutler.  Innate immunity: an overview. , 2004, Molecular immunology.

[38]  C. Delenda.  Lentiviral vectors: optimization of packaging, transduction and gene expression , 2004, The journal of gene medicine.

[39]  Andrea Vondracek,et al.  Generation and characterization of mice transgenic for human IL‐18‐binding protein isoform a , 2003, Journal of leukocyte biology.

[40]  Y. Iwakura,et al.  IL-1 Plays an Important Role in Lipid Metabolism by Regulating Insulin Levels under Physiological Conditions , 2003, The Journal of experimental medicine.

[41]  C. Saper,et al.  Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. , 2003, The Journal of physiology.

[42]  M. Rossmeisl,et al.  Variation in type 2 diabetes--related traits in mouse strains susceptible to diet-induced obesity. , 2003, Diabetes.

[43]  G. Fantuzzi,et al.  Interleukin-18 and host defense against infection. , 2003, The Journal of infectious diseases.

[44]  S. Olusi,et al.  Relations of Serum Interleukin 18 Levels to Serum Lipid and Glucose Concentrations in an Apparently Healthy Adult Population , 2003, Hormone Research in Paediatrics.

[45]  V. Giusti,et al.  Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. , 2003, Diabetes.

[46]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[47]  Sophie Janssens,et al.  Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. , 2003, Molecular cell.

[48]  C. Brosnan,et al.  Cytokines: Powerful Regulators of Glial Cell Activation , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[49]  S. Bahouth,et al.  Comparison of PGE2, prostacyclin and leptin release by human adipocytes versus explants of adipose tissue in primary culture. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.

[50]  D. Giugliano,et al.  Weight loss reduces interleukin-18 levels in obese women. , 2002, The Journal of clinical endocrinology and metabolism.

[51]  W. Arend.  The balance between IL-1 and IL-1Ra in disease. , 2002, Cytokine & growth factor reviews.

[52]  A. Golay,et al.  IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? , 2002, The Journal of clinical endocrinology and metabolism.

[53]  J. Sims.  IL-1 and IL-18 receptors, and their extended family. , 2002, Current opinion in immunology.

[54]  A. Tedgui,et al.  Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability , 2001, Circulation.

[55]  C. Brinckerhoff,et al.  Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta , 2001, Arthritis research.

[56]  J N Fain,et al.  Obesity is induced in mice heterozygous for cyclooxygenase-2. , 2001, Prostaglandins & other lipid mediators.

[57]  M Locati,et al.  Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. , 2001, Trends in immunology.

[58]  Adam Sapirstein,et al.  Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity , 2001, Nature.

[59]  R. Dantzer.  Cytokine‐Induced Sickness Behavior: Mechanisms and Implications , 2001, Annals of the New York Academy of Sciences.

[60]  C. Miething,et al.  Genomic Organization and Regulation of the Human Interleukin‐18 Gene , 2000, Scandinavian journal of immunology.

[61]  G. Sperk,et al.  Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  P. Neveu,et al.  Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1β , 2000, Journal of Neuroimmunology.

[63]  S. Rivkees,et al.  Regulation of leptin release and lipolysis by PGE2 in rat adipose tissue. , 2000, Prostaglandins & other lipid mediators.

[64]  E. Bruckert,et al.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. , 2000, The Journal of clinical endocrinology and metabolism.

[65]  W. Hofmann,et al.  IL-18 Activates STAT3 in the Natural Killer Cell Line 92, Augments Cytotoxic Activity, and Mediates IFN-γ Production by the Stress Kinase p38 and by the Extracellular Regulated Kinases p44erk-1 and p42erk-21 , 2000, The Journal of Immunology.

[66]  S. Akira.  Roles of STAT3 defined by tissue-specific gene targeting , 2000, Oncogene.

[67]  C. Brinckerhoff,et al.  Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. , 2000, Arthritis and rheumatism.

[68]  J. Gołąb.  Interleukin 18--interferon gamma inducing factor--a novel player in tumour immunotherapy? , 2000, Cytokine.

[69]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[70]  G. Fantuzzi,et al.  IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  S. Motzel,et al.  Influence of Blood Collection Sites on Plasma Glucose and Insulin Concentration in Conscious C57BL/6 Mice. , 1999, Contemporary topics in laboratory animal science.

[72]  A. Loudon,et al.  Leptin actions on food intake and body temperature are mediated by IL-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[73]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[74]  T. Born,et al.  Cloning of a Novel Receptor Subunit, AcPL, Required for Interleukin-18 Signaling* , 1998, The Journal of Biological Chemistry.

[75]  Atsushi Ichikawa,et al.  Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 , 1998, Nature.

[76]  G. Luheshi.  Cytokines and Fever: Mechanisms and Sites of Action , 1998, Annals of the New York Academy of Sciences.

[77]  S. Akira,et al.  Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. , 1998, Immunity.

[78]  T. Bártfai,et al.  Interleukin-1-mediated febrile responses in mice and interleukin-1 beta activation of NFkappaB in mouse primary astrocytes, involves the interleukin-1 receptor accessory protein. , 1998, European cytokine network.

[79]  F. Martinon,et al.  MyD88, an Adapter Protein Involved in Interleukin-1 Signaling* , 1998, The Journal of Biological Chemistry.

[80]  M Tomura,et al.  A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. , 1998, Journal of immunology.

[81]  Masatoshi Suzuki,et al.  Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion , 1998, The Journal of experimental medicine.

[82]  T. Bártfai,et al.  Interleukin‐1 System: Receptors, Ligands, and ICE in the Brain and Their Involvement in the Fever Response , 1998, Annals of the New York Academy of Sciences.

[83]  J. Regan,et al.  Prostanoid receptor heterogeneity through alternative mRNA splicing. , 1998, Life sciences.

[84]  M. Ikeda,et al.  Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. , 1998, Biochemical and biophysical research communications.

[85]  A. Strosberg,et al.  A leptin missense mutation associated with hypogonadism and morbid obesity , 1998, Nature Genetics.

[86]  K. Torigoe,et al.  Purification and Characterization of the Human Interleukin-18 Receptor* , 1997, The Journal of Biological Chemistry.

[87]  R. Kastelein,et al.  IGIF Does Not Drive Th1 Development but Synergizes with IL-12 for Interferon-γ Production and Activates IRAK and NFκB , 1997 .

[88]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[89]  M. Kurimoto,et al.  Interleukin-18 Activates NF-κB in Murine T Helper Type 1 Cells , 1997 .

[90]  G. Fantuzzi,et al.  Hyperresponsive febrile reactions to interleukin (IL) 1α and IL-1β, and altered brain cytokine mRNA and serum cytokine levels, in IL-1β-deficient mice , 1997 .

[91]  O. Hayaishi,et al.  CSF levels of prostaglandins, especially the level of prostaglandin D2, are correlated with increasing propensity towards sleep in rats , 1997, Brain Research.

[92]  H. Okamura,et al.  IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. , 1996, Journal of immunology.

[93]  T. Mandrup-Poulsen,et al.  The role of interleukin-1 in the pathogenesis of IDDM , 1996, Diabetologia.

[94]  N. Rothwell,et al.  Cytokines and fever. , 1996, International archives of allergy and immunology.

[95]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[96]  Y. Sugimoto,et al.  Prostaglandin E receptors. , 1995, Journal of lipid mediators and cell signalling.

[97]  A. Shaw,et al.  Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. , 1995, Immunity.

[98]  M. Labow,et al.  Molecular Cloning and Characterization of a Second Subunit of the Interleukin 1 Receptor Complex (*) , 1995, The Journal of Biological Chemistry.

[99]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[100]  S. Delikat,et al.  The metabolic effects of interleukin 1β on human bone marrow adipocytes , 1995 .

[101]  M. Dardenne,et al.  Localization and characterization of interleukin-1 receptors in the islets of Langerhans from control and nonobese diabetic mice. , 1995, Endocrinology.

[102]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[103]  A. Ford-hutchinson,et al.  Expression of mRNA for cyclooxygenase‐1 and cyclooxygenase‐2 in human tissues , 1993, FEBS letters.

[104]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[105]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[106]  T. Bártfai,et al.  Cytokines in neuronal cell types , 1993, Neurochemistry International.

[107]  B. Brouhard.  Cytokines and the pathogenesis of insulin-dependent diabetes mellitus. , 1992, Cleveland Clinic journal of medicine.

[108]  G. Fillion,et al.  Receptors for interleukin-1 (α and β) in mouse brain: Mapping and neuronal localization in hippocampus , 1991, Neuroscience.

[109]  R. Derijk,et al.  The immune-hypothalamo-pituitary-adrenal axis and autoimmunity. , 1991, The International journal of neuroscience.

[110]  K. Bendtzen,et al.  An interleukin-1 receptor antagonist protein protects insulin-producing Beta cells against suppressive effects of interleukin-1β , 1991, Diabetologia.

[111]  C. Wollheim,et al.  A natural interleukin 1 (IL-1) inhibitor counteracts the inhibitory effect of IL-1 on insulin production in cultured rat pancreatic islets. , 1989, Journal of autoimmunity.

[112]  J. Nerup,et al.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. , 1987, Journal of immunology.

[113]  J. Nerup,et al.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.

[114]  J. Watson,et al.  GENETIC CONTROL OF RESPONSES TO BACTERIAL LIPOPOLYSACCHARIDES IN MICE , 1974, The Journal of experimental medicine.

[115]  John N Fain,et al.  Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. , 2006, Vitamins and hormones.

[116]  T. Kielian.  Microglia and chemokines in infectious diseases of the nervous system: views and reviews. , 2004, Frontiers in bioscience : a journal and virtual library.

[117]  H. Joller-jemelka,et al.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[118]  C. Ohlsson,et al.  Interleukin-6-deficient mice develop mature-onset obesity , 2002, Nature Medicine.

[119]  P. Neveu,et al.  Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta. , 2000, Journal of neuroimmunology.

[120]  P. Ridker,et al.  C-reactive protein, inflammation, and coronary risk. , 2000, The Medical clinics of North America.

[121]  G. Fantuzzi,et al.  Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. , 1999, Immunity.

[122]  M. Goldenberg,et al.  Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. , 1999, Clinical therapeutics.

[123]  C. Gabay,et al.  Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.

[124]  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during , 1997 .

[125]  R. Kastelein,et al.  IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. , 1997, Immunity.

[126]  M Kurimoto,et al.  Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. , 1997, Biochemical and biophysical research communications.

[127]  G. Fantuzzi,et al.  Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[128]  S. Delikat,et al.  The metabolic effects of interleukin 1 beta on human bone marrow adipocytes. , 1995, Cytokine.

[129]  W. Fiers,et al.  Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. , 1992, Endocrinology.

[130]  G. Fillion,et al.  Receptors for interleukin-1 (alpha and beta) in mouse brain: mapping and neuronal localization in hippocampus. , 1991, Neuroscience.

[131]  K. Bendtzen,et al.  An interleukin-1 receptor antagonist protein protects insulin-producing beta cells against suppressive effects of interleukin-1 beta. , 1991, Diabetologia.

[132]  W. Kohr,et al.  Human tumor necrosis factor. , 1985, Methods in enzymology.